MarketPulse

epilepsy

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Supernus Pharmaceuticals Posts 39% Revenue Surge, CEO to Present at BofA Health Care Conference

Supernus Pharmaceuticals reports strong Q1 2026 results with $207.7M revenue, up 39% YoY. CEO Jack Khattar to present at Bank of America health care conference in May.
SUPNfinancial resultsrevenue growth
GlobeNewswire Inc.GlobeNewswire Inc.··Xenon Pharmaceuticals Inc.

Xenon's Seizure Drug Azetukalner Shows Strong Phase 3 Results Ahead of 2026 FDA Filing

Xenon Pharmaceuticals reports positive Phase 3 data for azetukalner in focal onset seizures, with 53.2% seizure reduction versus 10.4% placebo. FDA submission planned for Q3 2026.
XENEPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Rapport Therapeutics to Unveil RAP-219 Phase 2 Data for Seizure Treatment

Rapport Therapeutics will present Phase 2a follow-up data for experimental seizure drug RAP-219 at neurology conference in April 2026.
RAPPprecision medicinephase 2 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Xenon Pharma Raises $650M in Upsized Offering to Fund Pipeline Growth

Xenon Pharmaceuticals prices $650M upsized offering at $57/share with 10.5M shares. Proceeds fund pipeline acceleration; closes March 2026.
XENEpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Supernus to Present at Three Major Healthcare Conferences in March

Supernus Pharmaceuticals will present at three major healthcare conferences in March 2026, updating investors on strategic initiatives and operational progress.
SUPNinvestor conferencebiopharmaceutical